Pharmaceuticals

• Pfizer says obesity injection shows promise as monthly treatment in mid-stage trial - The data on Pfizer's GLP-1 offer early evidence that the injection can be administered less frequently than existing drugs without sacrificing efficacy.
• Pfizer beats quarterly estimates despite Covid product decline, reaffirms modest outlook - The pharmaceutical giant reaffirmed the modest 2026 outlook that rattled investors in December.
• Merck tops quarterly estimates, posts modest 2026 guidance as generic competition looms - Merck posted a modest 2026 outlook that fell short of estimates, as it prepares for some drugs to go off patent later this year and face generic competition.
• AstraZeneca is listing in New York, as Big Pharma balances the huge U.S. market with China's tempting innovation - AstraZeneca announces multibillion dollar investments in China as Big Pharma is increasingly looking east for innovation.
• Eli Lilly CEO says Medicare coverage of obesity drugs could 'change the game' for upcoming pill launch - Lilly CEO Dave Ricks is confident in the ability of the company's pill to compete and is preparing for a "full launch" in the second quarter.
• Drugmakers Roche and Sanofi talk up their pipelines, as earnings fail to excite - The drugmaker's full-year results didn't seem to move the needle for investors who are instead focused on future growth prospects and innovation
• What obesity drugmakers see next in the market: More pills, easier access and drug combinations - CNBC spoke to executives from Eli Lilly, Novo Nordisk, Pfizer and other drugmakers at the annual JPMorgan Healthcare Conference in San Francisco.
• From French drug pricing to 'loser' windmills: A rundown of who Trump criticized at Davos - U.S. President Donald Trump sharply criticized a number of current and former political leaders at the World Economic Forum in Davos.
• 2026 is the year of obesity pills. Here's how they could reshape the GLP-1 market - Patients can already access the first GLP-1 obesity pill from Novo Nordisk, and a rival oral drug from Eli Lilly is slated for U.S. approval later this year.
• Novo Nordisk's 'long game' on weight loss drugs sparks hope in science, but the Street is impatient - The medicine developed by the100-year old Danish drugmaker may impact patients' brains in surprising ways